四川省细胞生物学会理事

Frontiers of Medicine青年编委

1、 科研项目

（1）国家自然科学基金面上项目，可溶性CTLA-4在免疫相关不良反应（irAEs）中的作用机制与干预研究，2025-01至2028-12，49万元，主持。

（2）国家重点研发计划（青年项目），面向肺癌精准医疗的多模态肿瘤类器官芯片开发与智能决策系统构建，2024-12至2029-11，400万元，骨干。

（3）OncoC4, Inc研发基金，30033051，Developing anti-tumor antibodies targeting Siglec-10，2021-05 至2023- 05，280万元，主持。

2、 科研论文

（1）Mingyue Liu#; Xu Wang#; Xuexiang Du#; Wei Wu; Yan Zhang; Peng Zhang; Chunxia Ai; Martin Devenport; Juanjuan Su; Musleh M Muthana; Lishan Su; Yang Liu*; Pan Zheng*; Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4–and PD-1–targeted immunotherapy, Science Translational Medicine, 2023, 15(685): eabm5663

（2）Mingyue Liu#; Xu Wang#; Xuexiang Du; Yan Zhang; Chunxia Ai; Siwen Hu-Lieskovan; Tianhong Li; Martin Devenport; Yang Liu; Pan Zheng; CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect, Signal Transduction and Targeted Therapy, 2022, 7(1): 224.

（3）Xu Wang#; Mingyue Liu#; Jifeng Zhang; Nicholas K. Brown; Peng Zhang; Yan Zhang; Heng Liu;Xuexiang Du; Wei Wu; Martin Devenport; Weng Tao; Yang Mao-Draayer; Guo-Yun Chen; Y. Eugene Chen;Pan Zhen*g; Yang Liu*; CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder, Cell Metabolism, 2022, 34(8): 1088-1103.e6.

（4）Du Xuexiang#; Liu Mingyue#; Su Juanjuan; Zhang Peng; Tang Fei; Ye Peiying; Devenport

Martin; Wang Xu; Zhang Yan; Liu Yang*; Pan Zheng*; Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice, Cell Research, 2018, 28(4): 433-447.

（5）Yan Zhang#; Xuexiang Du#; Mingyue Liu#; Fei Tang; Peng Zhang; Chunxia Ai; James K. Fields; Eric J. Sundberg; Olga S. Latinovic; Martin Devenport; Pan Zheng*; Yang Liu*; Hijacking antibody induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy, Cell Research, 2019, 29(8): 609-627.

（6）Xu, Meng#; Liu, Mingyue#; Du, Xuexiang; Li, Sirui; Li, Hang; Li, Xiaozhu; Li, Ying; Wang,Yang; Qin, Zhihai; Fu, Yang-Xin; Wang, Shengdian; Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype, Journal of Immunology, 2015, 10(194): 4997-5006.

#共同第一作者，*共同通讯作者

3、发明专利

 （1）Yang Liu; Pan Zheng; Martin Devenport; Mingyue Liu; Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies, 2023-1-10, US11547741B2 ，美国、欧洲授权，转让默沙东公司。

（2）Yang Liu; Pan Zheng; Tang Fei; Mingyue Liu; Martin Devenport; Xuexiang Du; Yan Zhang; Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects, 2019-1-29, WIPO, PCT/US2019/015686. 美国、日本、新加坡、韩国授权.

（3）Yang Liu; Pan Zheng; Martin Devenport; Wei Wu; Xuexiang Du; Mingyue Liu; Fei Tang ; CD80 and CD86 binding protein compositions and uses thereof, 2023-3-1, US11261233B2 美国、中国授权。

（4）Yang Liu; Pan Zheng; Martin Devenport; Mingyue Liu; Anti-siglec compositions and uses thereof, 2022-4-29, WIPO, PCT/US2022/027006.，欧亚、台湾地区授权，获得OncoC4公司I期临床试验里程碑预付款。

（5）Yang Liu; Pan Zheng; Xu Wang; Mingyue Liu; Martin Devenport; Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis, 2020-2-05, WIPO,PCT/US2020/016881，转让默沙东公司。

（6）Yang Liu; Pan Zheng; Tang Fei; Mingyue Liu; Martin Devenport; Xuexiang Du; Yan Zhang; Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy, 2019-1-29, WIPO, PCT/US2019/015664.

所有发明人权益平等